ARREGIO BCIVALO T N MAX FAMB

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV524615838US Express Mail Label Number 10 May 2005 Date of Deposit

Form PTO-1390-MOD U. S. Department of Commerce Patent and Trademark Office (REV 10-96)		ATTORNEY'S DOCKET NUMBER ON/4-32759A				
TRANSMITTAL LETTER TO	THE UNITED STATES	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)				
DESIGNATED/ELECTED C	OFFICE (DO/EO/US)	4 0 / E 7 / / 23				
CONCERNING A FILING U		10/534427				
INTERNATIONAL APPLICATION NO. PCT/EP03/12594	INTERNATIONAL FILING DATE 11 November 2003 (11.11.03)	PRIORITY DATE CLAIMED 12 November 2002 (12.11.02)				
TITLE OF INVENTION	11 November 2003 (11.11.03)	12 November 2002 (12.11.02)				
4-AMINO-5-PHENYL-7-CYCLOHEXYL-PYF	ROLO[2,3-D]PYRIMIDINE DERIVA	TIVES				
APPLICANT(S) FOR DO/EO/US						
CAPRARO ET AL.						
Applicant herewith submits to the United States I	Designated/Elected Office (DO/EO/US) the	ne following items and other information:				
 This express request to begin national examination until the expiration of the application of the application of the application of the literature. A copy of the International Application of a literature of the literature. A copy of the International Application of the literature. A has been transmitted by the International Application of the International Application of the International Application. A translation of the International Application. Amendments to the claims of the International Application. are transmitted herewith (require beginning to the International Application. 	ubmission of items concerning a filing univamination procedures (35 U.S.C. 371(f) oplicable time limit set in 35 U.S.C. 371(b) only if not transmitted by the Internation of the International Bureau. (See Form PCT/IB/30 on was filed in the United States Receivingtion into English (35 U.S.C. 371(c)(2)). ational Application under PCT Article 19 (and only if not transmitted by the International Bureau. the time limit for making such amendment to be made. Claims under PCT Article 19 (35 U.S.C. 374 attorney (original or copy) (35 U.S.C. 374	at any time rather than delay and PCT Articles 22 and 39(1). The month from the earliest claimed priority all Bureau). By Office (RO/US). St. U.S.C.371(c)(3)). The priority and the earliest claimed priority all Bureau). The priority and the earliest claimed priority all Bureau). The priority and the earliest claimed priority all Bureau.				
Items 11. to 16. below concern document(s) o	r information included.					
11. An Information Disclosure Statement un	der 37 CFR 1.97 and 1.98.					
12.	A separate cover sheet in compliance w	with 37 CFR 3.28 and 3.31 is included.				
13. A FIRST preliminary amendment. A SECOND or SUBSEQUENT prelimina	ary amendment.					
14. 🛛 An Application Data Sheet under 37 CF	R 1.76.	•				
15. A substitute specification.						
16. A change of power of attorney and/or ac	Idress letter.					
17. A computer-readable form of the sequen	nce listing in accordance with PCT Rule	13ter.2 and 37 CFR 1.821-1.825.				
18. A second copy of the published Internat	ional Application under 35 U.S.C. 154(d)	(4).				
19. A second copy of the English language	translation of the International application	n under 35 U.S.C. 154(d)(4).				
20 Other items or information:						

JC14 Rec'd PCT/PTO 10 MAY 2005

U.S. APPLICATION	15347	127	PCT/EP03/12594 ON/4-3275										
The following fe	es are submitte	ed:							CALC	ULATIO	NS PTO USE		
									ONLY				
21. 🛭 Basi	☒ Basic national fee												
22. Examination	22. Examination Fee												
☐ If International preliminary examination report was prepared by USPTO													
and all claims satisfy provisions of PCT Article 33(1)-(4)													
⊠ Allo	ther situations.							\$200			_		
•													
23. Search fee													
If Search fee (37 CFR 1.445(a)(2)) has been paid on the international								\$					
application to the USPTO as an International Searching Authority \$ If International Search Report was prepared and provided to the Office \$400													
☐ All of	her situations.							\$					
		то	TAL OF	21, 22 AND 23	=				\$	900			
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer													
program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.										n			
Total Sheets	Extra sheet			ich additional 50 d up to a whole r		ו	R	ATE					
61 - 100 =	/50) =	or trouit	0	.airibel)	\dashv	X \$	250	\$				
0	00.5	- 44		-4: 1-1									
Surcharge of \$1 months from the					□ 30				\$				
CLAIMS		UMBER FIL		NUMBER EX	(TRA		RA	ΓΕ					
Total claims			- 20 =	0		X	\$	50	\$				
Independent cla		IM(S) (if an	- 3 =	0		<u>X</u>	<u>\$</u> \$	200 360	\$				
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$ 360 TOTAL OF ABOVE CALCULATIONS =									\$	900			
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be													
filed (Note 37 CFR 1.9, 1.27, 1.28).							\$	200					
SUBTOTAL =								\$	900				
Processing fee of \$130 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).							\$						
TOTAL NATIONAL FEE =							\$	900					
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied													
by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +							\$	900					
TOTAL FEES ENCLOSED =													
									nount to efunded	\$			
										charged	\$		
a. A check in the amount of \$ to cover the above fees is enclosed.													
b. Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$900 to cover the above fees. A duplicate copy of this form is enclosed.													
•											to		
Deposit Account No. 19-0134 in the name of Novartis.													
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.													
Sand all correspondence to the address associated with													
	Send all correspondence to the address associated with Customer No. 001095, which is currently:												
					1		- //	1 Nel	25 _				
Novartis							1cNally or Applic	ants	U				
Corporate Intellectual Property Reg. No. 36,214													
One Health Plaza, Building 104 (862) 778-7898 East Hanover, NJ 07936-1080													
205.110													